PubMed Health⌕ Search

Biomedical subjects

K H Wolffbrandt

Publications and source records attributed to K H Wolffbrandt.

5 recordsLinked to original sources
PubMed1986

A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.

The antithrombotic effects after intravenous administration of a low molecular weight heparin (LHN-1) and conventional heparin were compared in a rabbit model of experimental thrombosis, where thrombus formation was induced by a combination of endothelial damage and stasis. Both compounds were able to prevent thrombosis completely. However, LHN-1 was significantly less potent than conventional heparin, the ratio between doses with the same antithrombotic effect being 2.4:1 on a weight basis. Bleeding times after administration of LHN-1 and conventional heparin were determined by tail transsection in anaesthetized rats and by template bleeding in the ear of conscious pigs. Given intravenously at a dose ratio of 2.4:1 (w/w), LHN-1 affected APTT less than conventional heparin, whereas the effects on haemostasis were not significantly different. In conclusion, it was found that after intravenous administration LHN-1 prevented experimental thrombosis as effectively as conventional heparin. However, the correlation between antithrombotic and haemorrhagic effects of LHN-1 was the same as that of conventional heparin. The corresponding relation in man remains to be determined.

Animals↗
PubMed1986

Atriopeptin III improves renal functions in a ureter-obstructed rat kidney model.

The renal hemodynamic and excretory effects of atriopeptin III were studied in normal rat kidneys and in kidneys made dysfunctional by the application and release of a 24 h unilateral ureteral obstruction (UO24h), which decreased baseline glomerular filtration rate (GFR) by 80%. Atriopeptin III (0.5 nmol/kg i.v.) decreased blood pressure (10-15%) for more than 30 min, and increased urine flow rate and sodium excretion in normal and diseased kidneys for ca. 15 min. An initial enhancement of renal blood flow (ca. 20%) was apparent for less than 5 min. Atriopeptin III (bolus injection) temporarily enhanced the GFR 2-3-fold in the diseased (UO24h) kidneys, whereas no changes of GFR were noted in control kidneys. When atriopeptin III was continuously infused at a rate of 0.1 nmol/kg per min, GFR in UO24h kidneys increased from 0.28 +/- 0.08 ml/g per min to a stable level of 0.82 +/- 0.10 ml/g per min. Again, GFR in the control kidneys remained unaffected (1.25 +/- 0.08 ml/g per min). The enhancement of GFR in the UO24h kidney was associated with large increases of urine flow rate and sodium excretion.

Animals↗
PubMed1986

The effects of porcine GIP on insulin secretion and glucose clearance in the pig.

The present study was undertaken with the aims of studying the pharmacological effects and the pharmacokinetics of porcine GIP in pigs in vivo. Infusion of GIP and glucose resulted in a significant increase in the insulin release compared to the insulin release after glucose infusion in the control group. A significant increase in glucose clearance was also seen during GIP infusions. A two compartment open model with first order kinetics was used for the description of the pharmacokinetics of the infused GIP. The plasma half-life for GIP was found to be between 34-35 minutes.

Animals↗
PubMedDate not supplied

Improving the ethylene oxide sterilization process.

Although ethylene oxide (EtO) sterilization is commonly used in the manufacture of sterile medical devices, concern about residues of the sterilant in the sterilized products has led to an increase in the use of alternative methods; however, these methods, in turn, have significant drawbacks. The authors have tackled the issue by looking into the possibility of reducing EtO residuals. After conducting a series of investigative experiments, it has been proved that EtO residuals may be reduced by decreasing the amount of EtO used in the sterilization process. This can be achieved without lowering the safe sterility level and there are additional benefits for safety, cost, and the environment.

Ethylene Oxide↗